Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches - PubMed (original) (raw)

Review

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches

R S Kerbel et al. Cancer Metastasis Rev. 2001.

Abstract

The ultimate target of anti-angiogenic drugs is the genetically stable, activated endothelial cell of a newly forming tumor blood vessel, rather than the genetically unstable tumor cell population per se. This led to the notion that acquired resistance to such drugs may not develop as readily, if at all. While there is some evidence that this lack of resistance development may be the case for some direct-acting angiogenesis inhibitors, it is becoming apparent that resistance can develop over time to many types of angiogenesis inhibitors including, possibly, some direct inhibitors, especially when used as monotherapies. Possible mechanisms for such acquired or induced resistance include: (i) redundancy of pro-angiogenic growth factors when the drug used targets a single such growth factor or its cognate endothelial cell-associated receptor tyrosine kinase; (ii) the anti-apoptotic/pro-survival function of growth factors such as VEGF, which, in high local concentrations, can antagonize the pro-apoptotic effects of various angiogenesis inhibitors; (iii) epigenetic, transient upregulation, or induction, of various anti-apoptotic effector molecules in host-endothelial cells; and (iv) heterogeneous vascular dependence of tumor cell populations. It is suggested that long-term disease control with anti-angiogenic drugs can be best achieved by judicious combination therapy. In this regard, the great molecular diversity of anti-angiogenic drug targets, in contrast to chemotherapy, makes this a particularly attractive therapeutic option, especially when approved, commercially available drugs considered to have anti-angiogenic effects are used in such combination treatment strategies.

PubMed Disclaimer

Cited by

Transforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG.
Ling G, Wang S, Song Z, Sun X, Liu Y, Jiang X, Cai Y, Du M, Ke Y. Ling G, et al. Cancer Biol Ther. 2011 Dec 1;12(11):978-88. doi: 10.4161/cbt.12.11.18155. Epub 2011 Dec 1. Cancer Biol Ther. 2011. PMID: 22104964 Free PMC article.
Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma.
Sun Q, Wang Y, Ji H, Sun X, Xie S, Chen L, Li S, Zeng W, Chen R, Tang Q, Zuo J, Hou L, Hosaka K, Lu Y, Liu Y, Ye Y, Yang Y. Sun Q, et al. Cell Death Dis. 2022 Aug 19;13(8):724. doi: 10.1038/s41419-022-05171-3. Cell Death Dis. 2022. PMID: 35985991 Free PMC article.
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Pàez-Ribes M, et al. Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027. Cancer Cell. 2009. PMID: 19249680 Free PMC article.
Methotrexate-coupled nanoparticles and magnetic nanochemothermia for the relapse-free treatment of T24 bladder tumors.
Stapf M, Teichgräber U, Hilger I. Stapf M, et al. Int J Nanomedicine. 2017 Apr 6;12:2793-2811. doi: 10.2147/IJN.S120969. eCollection 2017. Int J Nanomedicine. 2017. PMID: 28435259 Free PMC article.
Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
Le TBU, Vu TC, Ho RZW, Prawira A, Wang L, Goh BC, Huynh H. Le TBU, et al. Int J Mol Sci. 2020 Dec 10;21(24):9405. doi: 10.3390/ijms21249405. Int J Mol Sci. 2020. PMID: 33321903 Free PMC article.

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches - PubMed (original) (raw)